Skip to main content

Coronavirus: Vaccination

Question for Department for Business, Energy and Industrial Strategy

UIN 148771, tabled on 3 February 2021

To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps he is taking to increase the UK’s long-term vaccine manufacturing capacity.

Answered on

12 February 2021

The Government has invested over £300 million to secure and scale up the UK’s manufacturing capabilities to be able to respond to the pandemic. This includes:

a) Facilities that have come online:

  • £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;
  • £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;
  • £65.5 million for the early manufacture of the University of Oxford / AstraZeneca vaccine; and
  • Funding for fill and finish through a contract with Wockhardt in Wrexham, North Wales which is currently providing fill and finish capabilities to the University of Oxford / AstraZeneca vaccine.

b) Facilities that will come online later this year, to help provide longer term UK capacity:

  • £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire; and
  • £127 million for the Cell and Gene Therapy Catapult in Braintree, Essex.

In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.